IRIS
LANDI, DORIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.294
AS - Asia 2.719
EU - Europa 2.037
SA - Sud America 418
Continente sconosciuto - Info sul continente non disponibili 249
AF - Africa 37
OC - Oceania 5
Totale 12.759
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.154
SG - Singapore 1.214
IT - Italia 963
CN - Cina 341
BR - Brasile 338
RU - Federazione Russa 315
HK - Hong Kong 270
BD - Bangladesh 250
VN - Vietnam 203
IE - Irlanda 197
KR - Corea 176
DE - Germania 102
JP - Giappone 102
GB - Regno Unito 79
NL - Olanda 79
FR - Francia 74
CA - Canada 70
UA - Ucraina 37
FI - Finlandia 36
IN - India 32
AR - Argentina 28
AT - Austria 27
SE - Svezia 27
IQ - Iraq 19
TR - Turchia 19
CH - Svizzera 18
ES - Italia 16
MX - Messico 16
EC - Ecuador 15
PL - Polonia 15
CO - Colombia 13
PK - Pakistan 13
MY - Malesia 12
ZA - Sudafrica 12
CR - Costa Rica 11
GR - Grecia 11
ID - Indonesia 11
EG - Egitto 9
CZ - Repubblica Ceca 8
CL - Cile 7
NI - Nicaragua 7
PY - Paraguay 7
RS - Serbia 7
UZ - Uzbekistan 7
GT - Guatemala 6
KG - Kirghizistan 6
PH - Filippine 6
RO - Romania 6
CW - ???statistics.table.value.countryCode.CW??? 5
DK - Danimarca 5
HN - Honduras 5
IR - Iran 5
SA - Arabia Saudita 5
VE - Venezuela 5
AU - Australia 4
AZ - Azerbaigian 4
MA - Marocco 4
PE - Perù 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
EE - Estonia 3
IL - Israele 3
KE - Kenya 3
PA - Panama 3
PR - Porto Rico 3
TH - Thailandia 3
AL - Albania 2
BB - Barbados 2
BS - Bahamas 2
DZ - Algeria 2
GP - Guadalupe 2
JM - Giamaica 2
JO - Giordania 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
NG - Nigeria 2
PT - Portogallo 2
QA - Qatar 2
SC - Seychelles 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BY - Bielorussia 1
CY - Cipro 1
DM - Dominica 1
ET - Etiopia 1
EU - Europa 1
GD - Grenada 1
GE - Georgia 1
GI - Gibilterra 1
HR - Croazia 1
LB - Libano 1
LT - Lituania 1
MM - Myanmar 1
NP - Nepal 1
Totale 12.510
Salva come PNG Salva come JPEG
Città #
Wilmington 1.237
Houston 975
Singapore 654
Woodbridge 528
San Jose 509
New York 403
Ashburn 381
Hong Kong 267
Chandler 198
Fairfield 179
Dublin 177
Beijing 138
Council Bluffs 131
Rome 124
Santa Clara 121
Los Angeles 110
Tokyo 90
The Dalles 83
Dallas 80
Milan 80
Ho Chi Minh City 76
North Bergen 75
Ann Arbor 65
Seattle 63
Buffalo 62
Medford 57
Roebling 55
Moscow 53
Cambridge 50
Hanoi 45
São Paulo 43
Naples 39
Lauterbourg 36
Denver 33
Dearborn 29
Lawrence 28
Turin 28
Chicago 24
Carrboro 22
Bologna 20
Nuremberg 20
San Diego 20
Atlanta 19
Lappeenranta 19
Phoenix 19
Florence 18
Jacksonville 16
Redondo Beach 16
Colorado Springs 15
Palermo 15
Brooklyn 13
London 13
Montreal 13
Piove di Sacco 13
San Francisco 13
Toronto 13
Creede 12
Vienna 12
Frankfurt am Main 11
Haiphong 11
Munich 11
Tampa 11
Elk Grove Village 10
Helsinki 10
Jakarta 10
Orem 10
Seoul 10
Warsaw 10
Bari 9
Belo Horizonte 9
Genoa 9
Kuala Lumpur 9
Mülheim 9
Palo Alto 9
San José 9
Bogotá 8
Brno 8
Columbus 8
Inverigo 8
Norwalk 8
Paris 8
Philadelphia 8
Redwood City 8
Salt Lake City 8
Brasília 7
Da Nang 7
Detroit 7
Johannesburg 7
Managua 7
Manchester 7
Mexico City 7
Rio de Janeiro 7
Verona 7
Amsterdam 6
Belgrade 6
Boardman 6
Charlotte 6
Chennai 6
Erbil 6
Lodi 6
Totale 7.991
Salva come PNG Salva come JPEG
Nome #
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML 530
TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis 520
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 462
Validity of the Italian multiple sclerosis neuropsychological screening questionnaire 421
Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course 380
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis 364
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 343
Miscarriage induces reactivation of inflammation in relapsing-remitting multiple sclerosis 337
Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis 334
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study 332
Safety, tolerability and effectiveness of dimethyl fumarate in multiple sclerosis: an independent, multicenter, real-world study 328
null 289
Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis 230
Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study 208
Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis 200
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression 199
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 199
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab 194
Functional assessment of outer and middle macular layers in multiple sclerosis 182
Anti-HBs titers are not decreased after treatment with oral Cladribine in patients with Multiple Sclerosis vaccinated against Hepatitis B virus 168
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab 160
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications 158
T-cell responses to SARS-CoV-2 in Multiple Sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-Spike antibody titers 157
Assessment of macular function by multifocal electroretinogram in patients with multiple sclerosis treated with fingolimod 152
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 142
Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis 142
Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis 138
Maternal Multiple Sclerosis and Offspring’s Developmental and Behavioral Profile: A Case-control Study 135
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 134
Correction to: Validity of the Italian multiple sclerosis neuropsychological screening questionnaire 126
Multifocal Electroretinogram Photopic Negative Response: A Reliable Paradigm to Detect Localized Retinal Ganglion Cells' Impairment in Retrobulbar Optic Neuritis Due to Multiple Sclerosis as a Model of Retinal Neurodegeneration 120
Patient's point of view on the use of telemedicine in multiple sclerosis: a web-based survey 114
COVID-19: dealing with a potential risk factor for chronic neurological disorders 114
Cortical ischemic lesion burden measured by DIR is related to carotid artery disease severity 112
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis 111
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) in the Italian population 107
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty 106
Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study 106
Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment 104
Complex epileptic palilalia: a case report 103
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 103
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 101
Association of vitamin D serum levels and vitamin D supplementation with B cell kinetics and disease activity in Multiple Sclerosis patients treated with ocrelizumab: an Italian multi-center study 100
Cognition is related to resting-state small-world network topology: an magnetoencephalographic study 99
Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection 98
Diagnostic value of JC polyomavirus viruria, viremia, serostatus and microRNA expression in multiple sclerosis patients undergoing immunosuppressive treatment 97
What happens after fingolimod discontinuation? A multicentre real-life experience 97
A specific anti-COVID-19 BNT162b2 vaccine-induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients 96
Phenotypic characterization of the placenta from women with Multiple Sclerosis exposed to Natalizumab during pregnancy. 90
Intra-cortical connectivity in multiple sclerosis: a neurophysiological approach 86
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis 86
A disease-specific convergence of host and Epstein-Barr virus genetics in multiple sclerosis 86
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 85
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy 84
Diffusion-weighted lesions after carotid artery stenting are associated with cognitive impairment 84
Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability 83
Cerebral restorative plasticity from normal ageing to brain diseases: a "never ending story" 83
Structural and Functional Assessment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes Without History of Optic Neuropathy 83
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT) 82
Ovarian reserve in patients with multiple sclerosis: A systematic review and meta-analysis 81
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 81
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study 80
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis 80
Cortico-muscular coherence as an index of fatigue in multiple sclerosis 79
Thalamocortical sensorimotor circuit in multiple sclerosis: an integrated structural and electrophysiological assessment 78
Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability 78
Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography 78
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study 78
Gender-related differences in functional connectivity in multiple sclerosis 75
Sex effects across the lifespan in women with multiple sclerosis 73
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 73
COVID-19 vaccine hesitancy among Italian people with multiple sclerosis 73
Skin Thickening of the Scalp and High Signal Intensity of Dentate Nucleus in Multiple Sclerosis: Association With Linear Versus Macrocyclic Gadolinium-Based Contrast Agents Administration 73
Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol 71
Therapeutic choices and disease activity after 2 years of treatment with cladribine: an Italian multicenter study (CladStop) 70
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 70
Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue." 68
Sars-CoV2 infection in pregnant women with multiple sclerosis 67
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders 65
Treatment modifiers across different regimens of natalizumab treatment in MS: an Italian real-world experience 64
Topographical Correlation between Structural and Functional Impairment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes with a History of Optic Neuropathy 63
Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing???remitting multiple sclerosis 61
fMRI-vs-MEG evaluation of post-stroke interhemispheric asymmetries in primary sensorimotor hand areas 61
Optimizing the "Time to pregnancy" in women with multiple sclerosis: the OPTIMUS Delphi survey 59
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 59
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 58
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis 57
Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine 54
Treatment discontinuation in older patients with multiple sclerosis 54
Dorsolateral medullary ischemic infarction causing autonomic dysfunction and headache: a case report 53
Functional connectivity changes in multiple sclerosis patients: a graph analytical study of MEG resting state data 50
Exposure to natalizumab during pregnancy and lactation is safe - Yes 47
Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue." 36
null 5
null 3
Totale 12.759
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.020
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.020
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022302 0 0 0 40 23 48 14 22 34 27 23 71
2022/20231.104 38 30 286 193 48 178 119 47 74 12 59 20
2023/2024451 101 10 22 23 32 64 35 12 28 23 11 90
2024/20252.078 61 375 180 142 62 212 144 88 220 273 180 141
2025/20263.702 274 214 397 199 324 99 493 421 392 272 338 279
2026/20271.547 244 166 618 519 0 0 0 0 0 0 0 0
Totale 12.759